NCT00198536 is a Phase 2/Phase 3 clinical trial of Ecabet 2.83% in Dry Eye Syndromes, sponsored by Bausch & Lomb Incorporated.

Who is sponsoring NCT00198536?

NCT00198536 is sponsored by Bausch & Lomb Incorporated.

What drugs are being tested in NCT00198536?

Interventions in NCT00198536: Ecabet 2.83%, Ecabet 3.70%, Vehicle.

What condition does NCT00198536 study?

NCT00198536 studies Dry Eye Syndromes.

Is NCT00198536 still recruiting?

NCT00198536 is currently completed. Last updated 13 March 2013.

Last reviewed 2013-03-13 · How we verify

NCT00198536

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Ecabet Ophthalmic Solution (2.83% and 3.70%) for Treatment of Dry Eye Syndrome

Completed Phase 2/Phase 3 Last updated 13 March 2013

What this trial tests

Phase 2/Phase 3 trial testing Ecabet 2.83% in Dry Eye Syndromes in 159 participants. Completed in 1 December 2005.

Timeline

1 April 2005

Primary endpoint
1 December 2005

1 December 2005

Quick facts

Lead sponsor	Bausch & Lomb Incorporated
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	159
Start date	1 April 2005
Primary completion	1 December 2005
Estimated completion	1 December 2005
Sites	3 locations across United States

Drugs / interventions tested

Ecabet 2.83% — full drug profile →
Ecabet 3.70% — full drug profile →
Vehicle

Conditions studied

Dry Eye Syndromes — all drugs for Dry Eye Syndromes →

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

18 and older, any sex, with Dry Eye Syndromes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Ocular discomfort
Time frame: Day 91
Group mean change in ocular discomfort score from pre-Cataract extraction (CAE) to post-CAE
Tear Film Break-up Time (TFBUT)
Time frame: Day 91
Group mean change in time to tear break-up from pre-CAE to post-CAE.
Blink Rate
Time frame: Day 91
Group mean change in blinks/min from pre-CAE to post-CAE.

Sponsor's own description

The purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Dry Eye Syndromes

Currently open trials in the same condition.

NCT07412860 — Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hy · NA · recruiting
NCT06913504 — Comparison Of Blue Light Filter Feature and Blue Blocking Lenses in Digital Device Users With Dry Eye Patients · NA · active not recruiting
NCT06913465 — The Impact of Hypothyroidism on Tear Production and Dry Eye Symptoms: Implications for Optometric Care · active not recruiting
NCT06831253 — Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome · NA · recruiting
NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects · NA · completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00198536 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 13 March 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00198536.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing